Member Info for Ivyspivey

Evening Crumbs,

The post 2015 AGM drop was totally different imo and the final drop to 3p though trended by a couple of lower placings on the journey was brought about by CF distressed situation.

This to me like others have said been triggered by someone or several desperate to get out and possibly either distressed or in RGs case on a time deadline.

Appreciate the difficult situation many will be feeling at the moment but Vulpes and RM will equally not be happy and do think there will be a lot of pressure on SCLP to address the situation.

The Investor Meet platform mention is a clear indication that SCLP wish to engage with SH but maybe the “ heavy drop in the SP” has just caused them to pause in order to see it play out as I imagine their reason for engagement is not related to the selling.

Rest= Reset

Hi Crumbs,

I am pleased your other share ( presume begins with an M and I have a small holding there) responded so well to the interview.

Always good to press the rest button once in a while and if you believe that overall the news was good and that you have a better idea of the risk/ reward moving forward then that gives you confidence especially from these levels.

I have sat through a few Investor Meet presentations on other shares and whilst they may not have time to handle all the posters questions then generally they are more informative than the Pro active ones

Miavoce possibly and that is why it may be a one off.

That is why an Investor Meet presentation I feel is on the cards and why that may be more telling as to how she comes across etc

Crumbs AB has highlighted the key issue it is the level of expectation bs the actual results.

As you say the non Ovarian results are very small cohorts so you should not make too many forward conclusions but LD did seem to switch focus from Moditope mono therapy to a more likely Combo approach so why was that as it appears a rest switch in focus and appeared to spook certain investors as evident by the selling since the news hit.

I take a different line that likes of RM and Vulpes will not be bothered as yes they will take a different view from many PIs but they will be concerned about the falling SP

Hi Crumbs and have to say hope you are feeling better as some of your recent posts have been heartfelt but at same time have raised some really good points of discussion.

Disappointing in response to the very high level of expectation that was anticipated by many investors on that next Modi update.So to expand.

There was no further significant shrinkage in moving the partial to a full response in tumour regression in HNC that some predicted.

There was no similar response in non Ovarian cancers to that one HNC trial patient that again some predicted would be “ inevitable”.

The trial recruitment numbers were very slow between the Feb and July update.

The comments regarding the main potential moving forward being using Modi as a Combination rather than a mono therapy after again some raising the bar based on mouse/ Trish result/ AGM comments.

Plus I feel the RNS covered a few areas not just the Modi update and was a bit if a catch all and not particularly well written as others have said.

My Tuppence worth for what it is worth.

I think SCLP recognised the need to bring in a more commercial CEO in CH and I thought he did OK but I also think that he saw himself as being the person to take SCLP onto the global stage and LD did not want him to get all the glory.Not because she resented anyone else getting the limelight but that she thinks no one understands or can explain her “ baby” as well as her.

After the “ power struggle” which she inevitably won she has found it difficult as anyone would to balance her responsibilities moving forward as SCLP is now a much different organisation in terms of size and complexity than the last time she was joint CEO.There is a long way to go but I could see signs in the RNS that shows a change is taking place.

The statement of prioritising the 2 platforms is imo clear evidence that there has been a strategic process going on within SCLP probably under the guidance of Cossery but also shows a willingness of LD to adapt and move forward.

I did think LD interview was lacklustre but that is my personal view and did affect sentiment based on not appearing as excited based on the heightened level of expectations that AB has already covered.

I am still very confident here but then again I have always considered the reward here to be significant and if the data proves compellling only then will I consider it stellar.

The results in Ovarian cancer were excellent and great to see a pathway for SCIB 1 but obviously the Modi mono therapy results in other cancers were disappointing but like AB I think that expectations were raised far too high based on AGM comments and the McM comments.

ATB

Hi TF,

Bermuda was just putting forward an alternative hypothesis which I believe has credence.The successful production and Approval of the mRNA Covid technology in a very short space of time backs Boris view of wanting to make the U.K. a Life Science superpower complete with a swift regulatory background.

Its main purpose is to attract incoming pharma investment hence the courting of Bion Tech.

Of course it should support SCLP and it has done so via the Innovate scheme but that is the difference. The U.K. Govt needs to support SCLP whereas the likes of Bion Tech support the U.K. Govt by providing investment not demanding it whilst the Govt provides a great regulatory background.

Until SCLP demonstrates via an RNS that for eg the Moditope platform can offer a comparable potential contribution to the likes of mRNA then we are simply speculating and we are still a very early stage drug development Company.

The development of the Covid Vaccine is a case in point the mRNA efforts got Approved and sold billions.The SCLP attempt although very promising did not get beyond p1.

Thanks Burble and as you say if Modi proves to be successful as we expect it could prove very valuable as a disruptive alternative as we know the benefits of a wider non personalised treatment in terms of value for money/ benefiting more patients etc.

But we need that update to conclude that we can offer that possibility and that is why the next news is so important.The significant mention and possible leaning of the U.K. Govt you highlight is of considerable interest here and indicative of the future but if results are good we will be well in the frame but I fully understand the concern of some if the Modi results are not as significant as we expect.

That is the dilemma we simply don’t know at this stage.

Morning,

Dracula for clarity we know Adrian had responded to the mRNA Vaccines as he was featured on the NW News Report along with Dr Rob Jones and Dr Sheena Khanduri, Medical Director of Clatterbridge who only commented on the mRNA Vaccine results.

But great that CO has given his thoughts and we look forward to the next Modi 1 update hopefully confirming that Modi I offers great potential as a cancer Vax treatment and gets equally good publicity.

Https://horizonteminerals.com/news/en_20230704_corporate-presentation.pdf

Sorry Icosavax and look at refs re bi valent Vaccine and developing a new CHIM to conduct a HC study.

Try looking at Isocovax

https://ir.icosavax.com/static-files/a6a59617-d6ec-4475-a3d6-6cdd3acf86b9

Evening WF just seen the longer version of the link you provided so thanks for that.

Adrian who is quoted said that following his last scan the Vaccine had virtually eliminated his tumour so a great result for him

As you say Hallsworthy we know typical manu of virus contracts then the characterisation study can easily be in order of £5-6m and then you have the actual study itself so your £10-15m range is imo eminently feasible.

We should find out more with the Isocovax SEC filings which should provide more detail.

First announcement in a while and has to be good news.

New model and client paying for it so expands range and enables only HVO to offer model so unique.As this virus is hard to do a normal field trial the use of a HC model is ideal for Go/ No go decision.

Not surprised there is no value attached as client will want to remain hidden and commercial sensitivity but we know roughly cost of developing and manu of CHIM and running a 36 bed zHC trial so we can guess but firstly they have to develop model and go from there.

Most will be 2024 revenue so has be good and will get an update at some stage

Hi Douve,

Theoretically they should have parity hence my arbitrage comment but you have to take into account that both on Nasdaq and AIM you can have other influencers such as “ speculation “ and excitement over different bits of news and you have all the normal games so US hedge funds buying and selling ADRs for their own ends.

So depends on who takes the ADRs.As Bermuda says the US is much more financially savvy re bio pharma but SCLP will be a very small fish in a huge pool and unless it hires good US IR firms to spread the message then it is hard to predict the SP movement.

However LD did say a Nasdaq listing would be considered on good results and that will determine outcome here and I am confident they will make right call.

If a Glycan deal happened that would be great but I presume NASDAQ is being touted as a way of taking Modi 1 forward without future dilution of a deal

Evening Bermuda,

Have not listened to I/ view yet so not sure if more context given to recruitment but would have thought getting a BDO would not have been that difficult unless they were after quite a Senior Appointment when you can understand why they may have had sone difficulty.

If that is the case plus the as you say long overdue CFO then that could indicate a clear attempt to support LD and improve the “ commercial” side of SCLP

Morning Douve.

Depends on listing so if a dual listing which I would expect then nothing just additional shares get issued in US and then apart from arbitrage then nothing changes.

If a single US listing which would totally surprise me then you would get offered a swap at sone agreed rate and then you decide to sell or hold.

Don’t forget we are already listed in Frankfurt if memory serves me right and that has no effect here but that is so lightly traded whereas even though SCLP would be dwarfed on Nasdaq it will hopefully attract much wider institutional interest

Moonparty.

Can’t remember if they have enough allocation to issue new shares this year but clearly on the agenda and we will all have to look for clues like any shelf registration/appointment of US outfits/ advisors like HC Wainwright etc .

Next Modi update is eagerly awaited as we can better judge the potential and bank of data must be getting to an interesting inflection point in the near future.